Sol-Gel Technologies (FRA:4SG) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4SG Sol-Gel Technologies Ltd FRA:4SG
58 GF Score
Price €65.00
GF Value €55.26
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Sol-Gel Technologies's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:4SG vs AVXL, FATE, FHTX: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Sol-Gel Technologies's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sol-Gel Technologies Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's Margin of Safety % (DCF Dividends Based) falls into.


FRA:4SG
58GF Score
Sol-Gel Technologies Ltd FRA:4SG
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sol-Gel Technologies (FRA:4SG) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of €65.00 is trading 17.6% above its estimated GF Value™ of €55.26. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for FRA:4SG:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €55.26 vs. price of €65.00 (17.6% above fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the FRA:4SG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges SLGL:USA
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
58GF Score

Get the complete analysis for FRA:4SG

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€55.26
GF Value